



## Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

March 24, 2022

PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#), ("Krystal") (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright's Gene Therapy and Gene Editing Conference and Guggenheim's 3<sup>rd</sup> Annual Genomic Medicines and Rare Disease Day.

Details for the events are as follows:

### H.C. Wainwright Gene Therapy and Gene Editing Conference

Presentation Date: Wednesday, March 30, 2022

Presentation Time: 7:00 a.m. EDT

Webcast Link: <https://journey.ct.events/view/5be9c8c9-116d-4777-b0f7-afc3aa88fd82>

A webcast of the presentation will be available for 90 days beginning at 7:00 a.m. on March 30. It will also be posted in the Investors section of the [Krystal Biotech website](#).

### Guggenheim 3<sup>rd</sup> Annual Genomic Medicines and Rare Disease Day

Fireside Chat Date: Thursday, March 31, 2022

Fireside Chat Time: 2-2:45 p.m. EDT

Webcast and Replay Link: <https://kvgo.com/guggenheim/krystal-biotech-inc-march-2022>

A replay of the fireside chat will be available via a link on the [Krystal Biotech website](#) approximately 48 hours after the event and will be viewable for 1 year.

### About Krystal Biotech

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit <http://www.krystalbio.com> and follow @KrystalBiotech on [LinkedIn](#) and [Twitter](#).

### CONTACTS:

#### Investors:

Whitney Ijem

Krystal Biotech

[wijem@krystalbio.com](mailto:wijem@krystalbio.com)

#### Media:

Tiffany Hamilton

Krystal Biotech

[thamilton@krystalbio.com](mailto:thamilton@krystalbio.com)



Source: Krystal Biotech, Inc.